Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant stock price inflation during the class period from October 10, 2025, to November 12, 2025 [8]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [8]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [8]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [8]. Stock Price Movement - Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news justifying such a spike [8]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [8]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [8].
CHARMING MEDICAL LAWSUIT REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds Charming Medical Limited Stockholders to Contact the Firm Before the February 17th Class Action Lead Plaintiff Deadline